PlasmarkAD® Pro is a breakthrough early detection solution using a simple blood test for Alzheimer’s disease (AD) and related pathology. Utilizing our proprietary machine learning algorithm, the PlasmarkAD® Pro test models the presence of brain amyloid-beta pathology with over 92% accuracy based on the levels of multiple AD-associated protein biomarkers (incorporating p-Tau 217, in accordance with the 2024 Revised Diagnosis Criteria from the Alzheimer’s Association). A positive brain amyloid-beta status is consistent with presence of amyloid plaques and Alzheimer’s disease diagnosis. PlasmarkAD Pro excels at distinguishing AD from other cognitive impairments, while also tracking disease progression to enable personalized management strategies.